Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) EPS (Weighted Average and Diluted) (2023 - 2025)

Historic EPS (Weighted Average and Diluted) for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$1.22.

  • Zenas BioPharma's EPS (Weighted Average and Diluted) rose 7569.72% to -$1.22 in Q3 2025 from the same period last year, while for Sep 2025 it was $13.67, marking a year-over-year increase of 12163.66%. This contributed to the annual value of -$12.22 for FY2024, which is 4959.08% up from last year.
  • As of Q3 2025, Zenas BioPharma's EPS (Weighted Average and Diluted) stood at -$1.22, which was up 7569.72% from -$1.25 recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's EPS (Weighted Average and Diluted) registered a high of $1.96 during Q3 2023, and its lowest value of -$24.23 during Q2 2024.
  • For the 3-year period, Zenas BioPharma's EPS (Weighted Average and Diluted) averaged around -$7.64, with its median value being -$4.28 (2024).
  • As far as peak fluctuations go, Zenas BioPharma's EPS (Weighted Average and Diluted) plummeted by 35612.24% in 2024, and later surged by 9552.82% in 2025.
  • Over the past 3 years, Zenas BioPharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$16.04 in 2023, then soared by 73.3% to -$4.28 in 2024, then soared by 71.52% to -$1.22 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$1.22 for Q3 2025, versus -$1.25 for Q2 2025 and -$0.8 for Q1 2025.